a developer of therapeutics for cancer treatment
Industry Biotechnology
A.I.dvisor tells us that MRUS and IMTX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRUS and IMTX's prices will move in lockstep.
Ticker / NAME | Correlation To MRUS | 1D Price Change % | ||
---|---|---|---|---|
MRUS | 100% | -1.36% | ||
IMTX - MRUS | 33% Poorly correlated | +1.06% | ||
RCKT - MRUS | 31% Poorly correlated | -2.25% | ||
NKTX - MRUS | 30% Poorly correlated | -4.59% | ||
TNYA - MRUS | 30% Poorly correlated | -5.43% | ||
CGEM - MRUS | 29% Poorly correlated | -1.44% | ||
More |
Ticker / NAME | Correlation To MRUS | 1D Price Change % |
---|---|---|
MRUS | 100% | -1.36% |
cancer theme (82 stocks) | 40% Loosely correlated | -2.38% |
treatment theme (56 stocks) | 39% Loosely correlated | -1.12% |
drugs theme (254 stocks) | 37% Loosely correlated | -1.72% |
therapeutics theme (53 stocks) | 29% Poorly correlated | -2.44% |
europe theme (179 stocks) | 24% Poorly correlated | -0.25% |
More |